Cyclodextrins are cylindrical oligosaccharides with a lipophilic central cavity and hydrophilic outer surface. They can form water-soluble complexes with lipophilic drugs, which 'hide' in the cavity. Cyclodextrins can be used to form aqueous eye drop solutions with lipophilic drugs, such as steroids and some carbonic anhydrase inhibitors. The cyclodextrins increase the water solubility of the drug, enhance drug absorption into the eye, improve aqueous stability and reduce local irritation. Cyclodextrins are useful excipients in eye drop formulations of various drugs, including steroids of any kind, carbonic anhydrase inhibitors, pilocarpine, cyclosporins, etc. Their use in ophthalmology has already begun and is likely to expand the selection of drugs available as eye drops. In this paper we review the properties of cyclodextrins and their application in eye drop formulations, of which their use in the formulation of dexamethasone eye drops is an example. Cyclodextrins have been used to formulate eye drops containing corticosteroids, such as dexamethasone, with levels of concentration and ocular absorption which, according to human and animal studies, are many times those seen with presently available formulations. Cyclodextrin-based dexamethasone eye drops are well tolerated in the eye and seem to provide a higher degree of bioavailability and clinical efficiency than the steroid eye drop formulations presently available. Such formulations offer the possibility of once per day application of corticosteroid eye drops after eye surgery, and more intensive topical steroid treatment in severe inflammation. While cyclodextrins have been known for more than a century, their use in ophthalmology is just starting. Cyclodextrins are useful excipients in eye drop formulations for a variety of lipophilic drugs. They will facilitate eye drop formulations for drugs that otherwise might not be available for topical use, while improving absorption and stability and decreasing local irritation.
ents is able to solubilize many lipophilic water-insoluble drugs which previously were impossible to formulate in aqueous eye drop solutions. Aqueous cyclodextrin containing eye drop solutions have already been registered in Europe. A chloramphenicol eye drop solution (ClorocilA) was recently registered in Portugal; 2001 saw the registration of a diclofenac eye drop solution (Voltaren OphthalmicA) in France. Previous reviews on this subject include those by van Dorne (1993); Rajewski & Stella (1996); Loftsson & Stefánsson (1997) ; and Loftsson & Järvinen (1999) . The object of this short review is to describe how cyclodextrins enhance aqueous solubility and bioavailability of lipophilic water-insoluble drugs in aqueous eye drop formulations. The formulation and in vivo testing of dexamethasone eye drops as performed within our own research group are used as examples.
Corticosteroids in ophthalmology
The most common use of corticosteroids in eye drops is for inflammation following eye surgery, such as cataract surgery and corneal operations. In mild cases it is usually adequate to apply the eye drops one to four times per day and in some cases topically applied nonsteroidal antiinflammatory drugs may be sufficient. However, in cases of severe inflammation, such as after complicated eye surgery, corneal transplant rejection or severe uveitis, applications as frequently as once every hour may not be adequate. In these severe cases the eye drops have to be supplemented with systemic steroids, such as prednisolone, or with subconjunctival or subtenon injection of steroids. Rather than using commercially available eye drops, it would then be more advantageous to use corticosteroid containing eye drops of greater bioavailability. Furthermore, topically applied corticosteroids are generally not effective in the posterior segment of the eye and, therefore, systemic corticosteroids are needed to fight inflammatory disease in this area.
Corticosteroids are generally lipophilic and dissolve very poorly in water. The commercially available eye drop formulations solve this dilemma by forming prodrugs, usually acetate or phosphate esters such as prednisolone acetate (Pred forte A, Pred mild A) and dexamethazone phosphate or suspensions, such as dexamethazone alcohol suspension (MaxidexA).
Various researchers have studied the penetration of topically applied ocular steroids into the anterior chamber of the human eye (Watson et al. 1988; McGhee et al. 1990 ). They found that of the commercially available formulations, those HPbCD Ω 2-hydroxypropyl-b-cyclodextrin aCD Ω a-cyclodextrin RMbCD Ω randomly methylated b-cyclodextrin SBEbCD Ω sulfobutylether b-cyclodextrin HPgCD Ω 2-hydroxypropyl-g-cyclodextrin DMbCD Ω heptakis (2,6-di-O-methyl)-b-cyclodextrin HEbCD Ω hydroxyethyl-b-cyclodextrin bCD Ω b-cyclodextrin gCD Ω g-cyclodextrin containing 1% prednisolone acetate (Pred forteA) gave the highest concentration in the aqueous humour per average 96 ng/ mL. Eye drops containing 0.1% dexamethasone alcohol suspension (MaxidexA) gave a considerably lower concentration. However, if we take into account the fact that dexamethasone is seven times more potent than prednisolone, then the dexamethasone concentration obtained in the aqueous humour corresponded to about 60 ng/mL of prednisolone. The most effective corticosteroid eye drops available today give aqueous humour concentration of less than 100 ng/mL (prednisolone equivalents). This bioavailability can be improved through the use of cyclodextrin formulation, where a single drop topical application gives aqueous humour concentration of about 140 ng/mL (prednisolone equivalents) and also extends its duration in the eye, as will be discussed later.
The corticosteroid concentrations achieved in the aqueous humour from application of Maxidex A or Pred Forte A is usually sufficient for mild to moderate ocular inflammation. More potent formulations may allow topical treatment of more severe intraocular inflammation and also less frequent applications for mild to moderate inflammation.
Physiological considerations
In ophthalmology, local drug administration in the form of topically applied low viscosity aqueous eye drop solutions is generally preferred. Topically applied drugs must be, at least to some degree, soluble in the aqueous tear fluid. However, they must also be somewhat lipidsoluble in order to penetrate the lipophilic corneal epithelium, through the corneal stroma and the lipophilic endothelium into the aqueous humour ( Common adjuvants to aqueous eye drop formulations can enhance ocular bioavailability of steroids by reducing the barrier function of, for example, the cornea (e.g. benzalkonium chloride and other surfactants (Lang & Stiemke 1996) or by increasing the contact time of the drug with the eye surface (e.g. viscosity enhancers such as water-soluble poly- mers). Specialized ocular delivery systems such as hydrogels, microemulsions, solid inserts and liposomes have also been designed in order to enhance bioavailability of topically applied ophthalmic drugs (Reddy 1996). However, these have never gained much popularity, due to both their side-effects (such as blurred vision and local irritation) and their instability (i.e. limited shelf-life).
Cyclodextrins are novel, chemically stable adjuvants that enhance ocular bioavailability of ophthalmic drugs without affecting the barrier function of the eye or increasing the viscosity of the aqueous eye drop formulation (Loftsson & Masson 2001) .
Cyclodextrins
Cyclodextrins are a group of structurally related natural products formed during bacterial digestion of cellulose. These cyclic oligosaccharides consist of (a-1,4)-linked a-D-glucopyranose units with a hydrophilic outer surface and a lipophilic central cavity. The natural a-, b-and gcyclodextrins consist of six, seven and eight glucopyranose units (Fig. 1) , respectively. The aqueous solubility of these natural cyclodextrins is somewhat limited and thus several different water-soluble derivatives have been synthesized. Cyclodextrin derivatives which have been applied in ophthalmology include the hydroxypropyl derivatives of b-and g-cyclodextrin, the randomly methylated bcyclodextrin and sulfobutylether b-cyclodextrin (Table 1) .
In an aqueous environment, cyclodextrins form inclusion complexes with many lipophilic molecules through a process in which water molecules located inside the central cavity are replaced by either a whole molecule, or, more frequently, by some lipophilic structure of the molecule. Cyclodextrin complexation of a drug molecule changes the physicochemical properties of the drug, such as its aqueous solubility and chemical stability (Loftsson & Brewster 1996) . Since the cyclodextrin molecule is hydrophilic on the outside, the complex formation usually increases the water-solubility of lipophilic water-insoluble drugs. Thus, it has been possible through cyclodextrin complexation to formulate lipophilic (Loftsson & Brewster 1996) . This increases the shelflife of the aqueous eye drop formulation. Once included in the cyclodextrin cavity, the drug molecules may be dissociated from the cyclodextrin molecules through complex dilution in the aqueous tear fluid. The included drug may also be replaced by some other suitable molecule (such as lipids), or, if the complex is located in close approximation to a lipophilic biological membrane (such as the eye cornea), the guest may be transferred to the matrix for which it has the highest affinity. Importantly, since no covalent bonds are formed or broken during the guest-host complex formation, the complexes are in dynamic equilibrium with free drug and cyclodextrin molecules.
The effects of cyclodextrins on drug solubility, permeability, chemical stability and delivery through biological mem- partition from the cyclodextrin cavity into the lipophilic membrane. The relatively lipophilic membrane has low affinity for the large hydrophilic cyclodextrin molecules or the hydrophilic drug/cyclodextrin complexes, which thus remain in the aqueous skin exterior, e.g. the aqueous tear fluid. Conventional penetration enhancers, such as benzalkonium chloride, disrupt the ophthalmic barrier, whereas hydrophilic cyclodextrins enhance drug penetration into the eye by carrying the lipophilic water-insoluble drug molecules through the aqueous mucin layer and thereby increasing drug availability at the lipophilic eye surface ( 
Formulation with cyclodextrin
Since neither cyclodextrins nor their complexes are absorbed into lipophilic barriers, cyclodextrins can both increase and decrease drug availability at the eye surface. For example, the effect of cyclodextrin concentration on the permeability of the lipophilic water-insoluble drug dexamethasone through semipermeable membrane is shown in Fig. 3 . At low cyclodextrin concentrations, when the drug is in suspension, the flux of the drug increases with increasing cyclodextrin concentration. At higher cyclodextrin concentrations, when the entire drug is in solution, the flux decreases with increasing cyclodextrin concentration. Maximum permeability is observed when just enough cyclodextrin is added to the vehicle to solubilize the entire drug. Figure  3 shows that it is very important to optimize the dexamethasone release from an aqueous eye drop formulation by adjusting the cyclodextrin concentration in the aqueous eye drop formulation. Too much or too little cyclodextrin will result in less than optimum drug availability. Some of the ingredients of the eye drop formulation will compete with dexa- methasone for a space in the cyclodextrin cavity, thereby reducing the solubilizing effect of the cyclodextrin. At the same time, some other ingredients may have a solubilizing effect on the drug, thereby reducing the amount of cyclodextrin needed to solubilize the drug. Consequently, the amount of cyclodextrin included in the aqueous eye drop formulation has to be based on availability studies performed on the actual eye drop formulation which must contain all necessary excipients (e.g. preservatives, polymers and buffer salts).
It is possible to increase drug availability in aqueous cyclodextrin formulations by including small amounts of water-soluble polymer. Polymers enhance the cyclodextrin complexation of the drug, thereby reducing the amount of cyclodextrin needed in the formulation, while simultaneously enhancing the absorption of the drug/cyclodextrin complex to the eye surface through the formation of ternary complexes or co-complexes (Kristinsson et al. 1996) . This increases the drug availability at the eye surface (Loftsson 1998; Loftsson & Järvinen 1999 ). The addition of 0.10% hydroxypropyl methylcellulose increases the apparent stability constant of dexamethasone/2-hydroxypropyl-bcyclodextrin complex from 1200  ª1 to 1600  ª1 (Loftsson & Stefánsson 1997 ). At the same time, the polymer increases the availability of dexamethasone in the aqueous eye drop formulation (Kristinsson et al. 1996). Using the described op-timization technologies, aqueous eye drops containing 0.32, 0.67 and 1.3% (w/ v) dexamethasone were prepared and tested both in animals and humans.
In vivo observations
Dexamethasone (1.3% w/v) was tested in English brown rabbits in an aqueous eye drop solution containing 2-hydroxypropyl-b-cyclodextrin and MaxidexA (Loftsson et al. 1994). A single drop of the solution was applied in the rabbit's eye and aqueous humour samples withdrawn at specified times following the administration. Dexamethasone (0.1% w/v) alcohol suspension (MaxidexA, Alcon Inc, Texas, USA) was used for control. The 1.3% dexamethasone/2-hydroxypropyl-b-cyclodextrin eye drops gave a significantly higher concentration of dexamethasone in the aqueous humour than did Maxidex, even though the difference in concentration in the aqueous humour was less than the 13-fold difference in the concentration of dexamethasone in the eye drop. Four hours after the application of MaxidexA, the concentration of dexamethasone in the aqueous humour was essentially zero, whereas the cyclodextrin-dexamethasone solution gave about 100 ng/mL (Fig. 4) . The cyclodextrin-dexamethasone eye drop solution was well tolerated and no irritation was seen on clinical examination of the rabbits.
The ocular absorption of dexamethasone eye drops containing 2-hydroxypropyl-b-cyclodextrin was also tested in human patients and compared with MaxidexA (0.1% dexamethasone alcohol suspension). The patients received the eye drops at a certain time prior to cataract surgery and, at the time of cataract surgery, an aqueous humour sample was withdrawn and dexamethasone levels determined. Figure 5 shows the dexamethasone concentration in the aqueous humour after administration of 0.32% dexamethasone/2-hydroxypropylb-cyclodextrin and MaxidexA (Kristinsson et al. 1996) . The concentration of dexamethasone in the aqueous humour was significantly higher (P Ͻ 0.001) and the area under the curve was 2.6 times higher with the 0.32% cyclodextrindexamethasone eye drop solution than with MaxidexA. The peak concentration of dexamethasone did not increase when the dexamethasone concentration in the aqueous cyclodextrin containing eye drops was increased from 0.32 to 0.67% (w/v) (Fig. 6) . However, as can be seen by concentration values obtained 9 hr after administration, the duration of activity was increased (Table 2) . It is interesting to compare these results with the measurements of Watson and associates and McGhee and associates (see Table 2 fective concentration in the aqueous humour than does prednisolone acetate, which is the most potent corticosteroid eye drop on the market. Figure 6 shows the effect of the cocomplexation involving the water-soluble polymer, hydroxypropyl methylcellulose, on the dexamethasone bioavailability in vivo. The two eye drop solutions were 
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Due to limited aqueous solubility of dorzolamide at physiologic pH, the pH of TrusoptR eye drops (cont. 2% dorzolamide) 14 has to be kept at about 5.65, and to increase the topical bioavailability of the drug from TrusoptR the contact time of the drug 15 with the eye surface is increased by increasing the viscosity of the eye drops to 100 cps. This low pH and high viscosity can lead 16 to local irritation. In this study, dorzolamide hydrochloride was formulated as 2% and 4% low viscosity solutions (viscosity 3 to 17 5 cps) containing randomly methylated h-cyclodextrin at pH 7.45. These formulations were evaluated in rabbits. The animals 18 were sacrificed at various time points after topical administration of the drug and the dorzolamide concentration determined in 19 the different parts of the eye. TrusoptR was used as a reference standard. The topical availability of dorzolamide from the 20 cyclodextrin-containing eye drops appeared to be comparable to that from TrusoptR and the drug reached retina and optic nerve 21 to give measurable concentrations for at least 8 h after administration of the eye drops. [21] . Measuring the effect of dorzolamide 101 on the blood flow in retina and optic nerve is rather 102 difficult and therefore it is easy to miss this effect.
103 One aspect of this study is to show that it is possible 104 that dorzolamide has a direct effect on the human CA 105 isoenzyme II in the back of the eye. 106 Cyclodextrins are cyclic oligosaccharides with a 107 hydrophilic outer surface and a lipophilic cavity in 108 the center. They are able form water-soluble drug/ 109 cyclodextrin inclusion complexes of lipophilic water-110 insoluble drugs. No covalent bounds are formed or 111 broken during the complex formation, and in 112 aqueous solution the complexes are readily dissoci-113 ated upon dilution. In general, cyclodextrin mole-114 cules do not penetrate biological membranes but act 115 as penetration enhancers by assuring high concen-116 tration of dissolved drug at the membrane surface.
117 Cyclodextrins increase the aqueous solubility of 
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118 lipophilic water-insoluble drugs without decreasing 119 the intrinsic ability of the lipophilic drug molecules 120 to penetrate lipophilic biological membranes. Cyclo-121 dextrin can act as a drug carrier that delivers the 122 drug molecule through the aqueous exterior of the 123 membrane, i.e., the mucin layer, and releases it to the 124 relatively lipophilic biological membrane such as the 125 cornea [22] . Cyclodextrins do not disrupt the 126 ophthalmic barrier like conventional penetration 127 enhancers do (like, for example, benzalkonium 128 chloride) [23] . Care must be taken to use the right 129 amount of cyclodextrin since too much cyclodextrin 130 can decrease topical bioavailability of drugs.
131
The purpose of this study was to formulate low 132 viscosity aqueous dorzolamide eye drop solution 133 containing the unionized drug at pH 7.45 using 134 randomly methylated h-cyclodextrin (RMhCD) as a 135 solubilizer, and to evaluate the formulations in rabbits.
136 In a previous study we have used RMhCD to 137 solubilize dexamethasone in aqueous eye drop sol-138 utions and shown that eye drops containing RMhCD 139 are well tolerated in humans [24] . 
142
Dorzolamide HCl, internal standard (L-662614-143 002J005) and TrusoptR eye drops were obtained from 144 Merck (USA). Randomly methylated h-cyclodextrin 145 with some degree of substitution 1.8 (RMhCD) was 146 purchased from Wacker-Chemie GmbH (Germany). 147 Analytical grades of disodium phosphate dihydrate, 148 monosodium phosphate monohydrate and disodium 149 edetate dihydrate (EDTA) were purchased from 150 Merck (Germany). Hydroxypropyl methylcellulose 151 (HPMC) was obtained from Mecobenzon (Denmark). 152 Benzalkonium chloride was purchased from Sigma 153 (USA). All other chemicals used in this study were 154 commercially available compounds of special reagent 155 or analytical grade.
2.2. Solubility studies

157
Phase-solubility study was performed to deter-158 mine the exact mount of RMhCD needed to 159 solubilize dorzolamide at neutral pH. An excess 160 amount of dorzolamide HCl was added to aqueous 161 phosphate buffer pH 8.0 (0.05 M). The buffer 162 contained 0% to 20% (w/v) RMhCD, benzalkonium 163 chloride (0.02% w/v), EDTA (0.1% w/v) and HPMC 164 (0.1%). The pH of the solution was adjusted to pH 7.5 165 with 10 M NaOH. The suspensions formed were heated 166 in an autoclave (Midmark M7 SpeedClave) in sealed 167 containers to 121 8C for 20 min. The suspensions were 168 allowed to cool to room temperature (22-23 8C) and 169 equilibrate for 7 days. After equilibrium was attained, 170 the suspension was filtered through a 0.45-Am mem-171 brane filter, diluted and analyzed by HPLC. The pH 172 was also determined at room temperature at the end of 173 the equilibration period. To prevent drug precipitation 174 during storage, 10% excess RMhCD was included in 175 the aqueous eye drop formulation. Unanaesthetized pigmented rabbits, fed on a 210 regular diet, were placed in restraint boxes. The study 211 adhered to the ARVO declaration for the use of 212 laboratory animals in research. One drop (50 Al) of 213 each eye drop solution was administered to both eyes. 214 Six rabbits were sacrificed at each time point, at 1, 2, 215 4 and 8 h. Samples were taken from both eyes, in all 216 72 rabbits (144 eyes). The rabbits were sacrificed by 217 intravenous injection of sodium pentobarbital and the 218 eyes were proposed and enucleated immediately and 219 rinsed with an isotonic saline solution. Six rabbits 220 (control group) received saline eye drops devoid of 221 dorzolamide and their eyes were enucleated 2 h after 222 application. 
224
The aqueous humor was removed from the eye 225 using 1-ml syringe attached to a 26-G needle. The 226 cornea was cut from the limbus with scissors and 227 placed in a sampling bottle, and the iris into another 228 bottle. The lens was removed and placed in a separate 229 sampling bottle. The vitreous humor was emptied into 230 a sampling bottle by turning the eye backside up. Four 231 incisions (anterior to posterior) were performed in the 232 sclera to open the eye totally and remove the ciliary 233 body. The retina was gently scraped away and placed 234 in a sampling bottle. The optic nerve was removed 235 and placed in a sampling bottle. Great care was taken 236 to prevent cross-contamination between individual 237 tissue samples and eye fluids. While dissecting the 238 eyes, all the samples were put immediately into small, 239 dry polypropylene bottles, which were then immersed 240 in liquid nitrogen. Following the finishing dissection 241 of each rabbit, the samples were moved from the 242 liquid nitrogen and stored at À70 8C. Identical tissues 243 from each pair of eyes were pooled for the dorzola-244 mide concentration measurement and the number of 245 samples for each time point was therefore six.
246
After weighing or pipetting into culture tubes, the 247 samples were spiked with an internal standard 248 solution. The samples were buffered to pH 8 with 249 0.2 M Tris buffer, followed by extraction into ethyl 250 acetate. After centrifugation, the organic phase was 251 transferred into culture tubes. 
The HPLC method was validated with respect to 297 sensitivity, linearity, accuracy and precision before the 298 start of study. The lower limit of quantification was set 299 at 0.10 Ag/ml (precision 0.84%, accuracy 11.1%). 300 Linearity was confirmed over the concentration range 301 of 0.1 to 10 Ag/ml (r 2 0.9999-1.000). Intra-assay 302 accuracy (À9.2% to À0.6%), intra-assay precision 303 (0.3% to 5.5%), inter-assay accuracy (À4.3% to 304 1.1%), and inter-assay precision (2.1-7.9%) were all 305 within the set requirements for the analysts. 
307
Dorzolamide has two pK a values of 6.35 (pK a1 ) 308 and 8.5 (pK a2 ) corresponding to the protonized 309 secondary amino group and the sulfonamide group, 310 respectively (Fig. 1) . It is mainly in its hydrophilic 311 cationic form at pH below 6.4 and mainly in its 312 hydrophilic anionic form at pH above 8.5. The largest 313 fraction of the lipophilic unionized form exists at pH 314 right between the two pK a values or at pH 7.45. 315 Dorzolamide exists in two polymorphic forms: form I 316 which is the more thermodynamically stable form and 317 form II which is slightly more soluble in water. 318 Solubility in water at room temperature (~23 8C) was 319 determined to be about 40 mg/ml at pH 4.0-5.5. The 320 commercial product contains 2.25% (w/v) of the 321 hydrophilic hydrochloride salt in an aqueous pH 338 5.65 citrate buffer solution, and to prevent precip-339 itation the pH has to be maintained below 5.8. 
341
The aqueous solubility of dorzolamide is a function 342 of the ionization constants of the drug molecule. The 343 pH solubility profile for dorzolamide with and without 344 5% RMhCD is shown in Fig. 2 . The solubility of the 345 drug molecule is lowest just right between the two 346 ionization constants or at pH about 7.4. Fig. 3 
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368 aqueous isotonic 4% dorzolamide/RMhCD eye drop 369 solution at pH 7.4 by using the free dorzolamide base. 370 However, the free base was not available. 371 TrusoptR is relatively a viscous solution; the 372 viscosity was determined to be about 100 cps. The 373 viscosity of 2% and 4% eye drops is very low or about 374 3 and 5 cps, respectively. For comparison, the 375 viscosity of water is 1 cps. 376 3.2. In vivo evaluation
377
All solutions were well tolerated by the rabbits and 378 no macroscopic signs of irritation, redness or other 379 toxic effects were observed. Dorzolamide was 380 absorbed from all three test and control formulations 381 into the anterior part of the eye. The results are 382 summarized in Table 1 . Dorzolamide was detected in 383 most samples from retina and optic nerve in meas-384 urable concentrations but in very few samples from 385 vitreous humor. Differences in concentration between 386 the three formulations did not reach statistical 387 significance due to the variability and relatively low 388 number of data points. The results indicated that after 389 1 and 2 h, the 4% (w/v) dorzolamide RMhCD 390 solution was superior in the back of the eye (i.e., 391 retina and optic nerve), while TrusoptR was superior 392 in the front of the eye (i.e., cornea, aqueous humor, 393 iris and corpus ciliare). In retina and optic nerve, the 394 4% dorzolamide cyclodextrin formulation gave mean 395 (Fstandard deviation) concentration/tissue weight 396 (Ag/g) of 1.04 (F0.59) and 2.8 (F1.4) after 2 h, while 397 TrusoptR gave 0.52 (F0.34) and 1.78 (F1.53), 398 respectively. In cornea and iris-ciliary body the 4% 
